CClinicalTrials.gg
CompletedNCT05684913Updated Jan 13, 2023

The Effects of Zn-containing Granulate on Patient Morbidity and Wound Healing After Free Gingival Graft Surgery

An interventional study of Zn granulate stent after FGG surgery and Hemostatic agent suturing in Surgery, sponsored by Cukurova University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-13.

Sponsored by Cukurova University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2022, registered Dec 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

There is no study in the literature showing the effects of Zn on wound healing after free gingival graft (FGG) operation. The aim of this randomized clinical study was to compare the early healing results of the palatal wound after FGG harvesting by sterile hemostatic agent suturing or the use of surgical stent from thermoplastic Zn-containing granules which was prepared chairside.

Read the detailed description

There are many studies reporting paresthesia, herpetic lesion, mucocele, excessive bleeding and severe postoperative pain after procedure.The highest pain level perceived in the palatal region after the FGG operation is experienced on the first day after the operation and decreases to the preoperative levels approximately 2 weeks after the operation. Although hemostatics, bioactive substances, antibacterial and antiseptic agents, herbal effective products, platelet concentrations, low-dose laser applications, palatal stents are used in the palatal region to accelerate the healing stages and prevent such complications, an ideal support has not been found.

02

Conditions studied

  • Surgery

Keywords

  • free gingival graft surgery
  • surgical stent
  • zinc
  • pain
  • bleeding
03

In context

Lead sponsor

Cukurova University is the lead sponsor of 247 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Periodontal and systemically healthy

    • ≥19 years old
    • Amount of attached gingival width in the maxillary or mandibular anterior region \<2 mm
    • Full mouth plaque index score, bleeding index score on full-mouth probing \<15%

Exclusion criteria

Exclusion criteria;

  • Previously undergone surgery for a graft harvested from the palate
  • Presence of systemic disease
  • Taking medication known to interfere with periodontal health
  • Smoking
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Zinc granulate group

    The patients in this group will receive a chair-side prepared surgical stent from Zn granulates on the palatal wound after FGG surgery.

    Procedure: Zn granulate stent after FGG surgery

  • Active comparator
    Hemostatic agent group

    The patients in this group will receive hemostatic agent sutured on the palatal wound after FGG surgery.

    Procedure: Hemostatic agent suturing

Interventions

  • ProcedureZn granulate stent after FGG surgery

    Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes and the ZnG was prepared according to the manufacturer guidelines. Briefly, approximately 10 grams of granulate was poured into hot water and then manually shaped to cover the surgical area. The retention was achieved from the palatal, occlusal and buccal surfaces of the teeth. The patient was asked to wear the ZnG for 7 days except for eating.(

  • ProcedureHemostatic agent suturing

    Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes. Then hemostatic agent containing cellulose were sutured on the palatal wound area with 4.0 vicryl sutures in this group. Sutures were removed after 7 days.

06

What researchers measure

Primary outcomes

  1. Post-operative pain

    Pain was scored from 0 to 10 experienced by the patients as a result of palatal wound (0: no pain, 1: minimal pain, 10: severe pain).

    Time frame: post operative 8 weeks

Secondary outcomes

  1. Bleeding

    Bleeding of the palatal wound was described as prolonged hemorrhaging after the surgery and was recorded 'yes' or 'no'

    Time frame: post operative 7 days

  2. Burning sensation

    BS was assessed as the level of sense of burning of the palatal wound via Visual Analogue Scale (0:absent 10:severe burning)

    Time frame: post operative 8 weeks

  3. Change in dietary habits

    evaluated according to inability to chew resulting from the presence of the palatal wound via Visual Analogue Scale (0: no changes 10: not capable of eating)

    Time frame: post operative 8 weeks

  4. Complete epithelization

    evaluated clinically with the 3% Hydrogen Peroxide test. While the H2O2 epithelial barrier is intact, it doesn't diffuse into the connective tissue, and oxygen isn't released. The absence of bubbles after H2O2 application was considered as CE positive, and CE was recorded as a triple variable

    Time frame: post-operative 8 weeks

  5. Patient discomfort

    PD was assessed by application of air spray for 5 seconds over the palatal site and then patients scored the VAS considering sensitive function (0: no discomfort, 10: extreme).

    Time frame: post-operative 8 weeks

07

Study locations

1 site
  • Cukurova University Faculty of Dentistry
    Adana, 01330, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05684913
Lead sponsor
Cukurova University
Responsible party
Mustafa Ozcan (Associate Professor, Cukurova University) — Principal investigator
First posted
Jan 13, 2023
Start date
Mar 20, 2022
Primary completion
Nov 15, 2022
Completion
Dec 10, 2022
Last update
Jan 13, 2023

Study contacts

Cenk Haytac
study director · Professor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion